AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27118223 — intervention group
Group type: COMPARATOR
Intervention: Canon EOS 10D anterior segment camera
Number of subjects: 440
Study 24901857 — intervention group
Group type: EXPERIMENTAL
Intervention: MPSS plus rhEPO (500 unit/kg on admission and another 500 unit/kg 24 hours later)
Number of subjects: 30
Study 24901857 — intervention group
Group type: COMPARATOR
Intervention: MPSS alone (30 mg/kg initially and 5.4 mg/kg every hour till 23 hours if admitted within 3 hours and till 47 hours if recruited within 3-6 hours)
Number of subjects: 30
Study 23104122 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ALS
Number of subjects: 2394
Study 23104122 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 2394
Study 23104122 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouses of ALS patients
Number of subjects: 2394
Study 22010243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannan-oligosaccharides (MOS) 0.5%
Number of subjects: 250
Study 22010243 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (PM) 0.1%
Number of subjects: 250
Study 22010243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MOS and PM (SYN)
Number of subjects: 250
Study 22010243 — intervention group
Group type: COMPARATOR
Intervention: Control (Corn-based diet without supplementation)
Number of subjects: 250
Study 18926059 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice a day for 6 weeks)
Number of subjects: 36
Study 18926059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16408169 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac suppository
Number of subjects: 228
Study 16408169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 16408169 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study 16408169 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac group
Number of subjects: 228
Study 14524654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (Xyrem)
Number of subjects: 140000
Study 10716359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lund and Browder charts
Number of subjects: 0
Study 10716359 — intervention group
Group type: COMPARATOR
Intervention: Rule of Nine's diagrams
Number of subjects: 0
Study 10716359 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn experience
Number of subjects: 0
Study 10716359 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn shape and location
Number of subjects: 0
Study 8956025 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS levels
Number of subjects: 564
Study 8956025 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption, reproductive status, body composition, HDL3 levels
Number of subjects: 564
Study 8956025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex and age
Number of subjects: 564
Study 1340107 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane (PU) catheters
Number of subjects: 300
Study 1340107 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene (PE) catheters
Number of subjects: 300
Study 2860283 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg in soft gelatine capsule
Number of subjects: 12
Study 2860283 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg in uncoated tablet
Number of subjects: 12
Study 2860283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31374208 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastance-directed indwelling pleural catheter (EDIT)
Number of subjects: 31
Study 31374208 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Talc slurry pleurodesis, TSP)
Number of subjects: 31
Study 31374208 — intervention group
Group type: EXPERIMENTAL
Intervention: PEL assessment during large-volume thoracentesis
Number of subjects: 31
Study 28783865 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule A (4 mg)
Number of subjects: 20
Study 28783865 — intervention group
Group type: COMPARATOR
Intervention: Capsule B (4 mg)
Number of subjects: 20
Study 27310949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest TA-SUA group (<5.5 mg/dL)
Number of subjects: 1738
Study 27310949 — intervention group
Group type: COMPARATOR
Intervention: Middle 3 TA-SUA groups (5.5-8.4 mg/dL)
Number of subjects: 1738
Study 27310949 — intervention group
Group type: COMPARATOR
Intervention: Highest TA-SUA group (≥8.5 mg/dL)
Number of subjects: 1738
Study 25085225 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartQuit (ACT application)
Number of subjects: 196
Study 25085225 — intervention group
Group type: COMPARATOR
Intervention: QuitGuide (NCI application)
Number of subjects: 196
Study 25085225 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartQuit (ACT application) among low acceptance of cravings
Number of subjects: 196
Study 25085225 — intervention group
Group type: COMPARATOR
Intervention: QuitGuide (NCI application) among low acceptance of cravings
Number of subjects: 196
Study 22718556 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 µg/kg/min PGE(2) (Prostin(®)E2, dinoprostone)
Number of subjects: 12
Study 22718556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19164498 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 16
Study 19164498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (maintained at 0.6 per thousand for 3 h)
Number of subjects: 16
Study 19164498 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of MDMA and ethanol
Number of subjects: 16
Study 19164498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17392551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (32 mg/day)
Number of subjects: 40
Study 17392551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16353319 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐E2/0.125 mg TMG
Number of subjects: 100
Study 16353319 — intervention group
Group type: COMPARATOR
Intervention: 1 mg 17beta‐E2/0.5 mg NETA
Number of subjects: 100
Study 16353319 — intervention group
Group type: COMPARATOR
Intervention: 2 mg 17beta‐E2/1 mg NETA
Number of subjects: 100
Study 12072873 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn Individualized Developmental Care and Assessment Program (NIDCAP)
Number of subjects: 321
Study 12072873 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 321
Study 9786602 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (nisoldipine or benidipine)
Number of subjects: 86
Study 9786602 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACEI) (captopril or imidapril)
Number of subjects: 86
Study 9786602 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-receptor blockers (arotinolol or bisoprolol)
Number of subjects: 86
Study 9786602 — intervention group
Group type: EXPERIMENTAL
Intervention: All antihypertensive agents
Number of subjects: 86
Study 9786602 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI
Number of subjects: 86
Study 9786602 — intervention group
Group type: EXPERIMENTAL
Intervention: Arotinolol and bisoprolol
Number of subjects: 86
Study 7665814 — intervention group
Group type: EXPERIMENTAL
Intervention: Current medical therapy for severe ulcerative colitis
Number of subjects: 374
Study 7665814 — intervention group
Group type: EXPERIMENTAL
Intervention: Current medical therapy for severe Crohn's colitis
Number of subjects: 374
Study 2764289 — intervention group
Group type: COMPARATOR
Intervention: Room air for 10 min after arrival in the RR
Number of subjects: 209
Study 2764289 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% O2 for 10 min after arrival in the RR
Number of subjects: 209
Study 2764289 — intervention group
Group type: COMPARATOR
Intervention: Room air for 10 min at 20 min after arrival in the RR
Number of subjects: 209
Study 2764289 — intervention group
Group type: COMPARATOR
Intervention: Room air for 10 min at 1 hr after arrival in the RR
Number of subjects: 209
Study 29164377 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.25 mg/day DHEA
Number of subjects: 345
Study 29164377 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg/day DHEA
Number of subjects: 345
Study 29164377 — intervention group
Group type: COMPARATOR
Intervention: Plain moisturizer (PM)
Number of subjects: 345
Study 28935079 — intervention group
Group type: EXPERIMENTAL
Intervention: BRS with post-dilatation
Number of subjects: 191
Study 28935079 — intervention group
Group type: EXPERIMENTAL
Intervention: BRS without post-dilatation
Number of subjects: 191
Study 28935079 — intervention group
Group type: EXPERIMENTAL
Intervention: EES with post-dilatation
Number of subjects: 191
Study 28935079 — intervention group
Group type: EXPERIMENTAL
Intervention: EES without post-dilatation
Number of subjects: 191
Study 28935079 — intervention group
Group type: COMPARATOR
Intervention: BRS
Number of subjects: 191
Study 28935079 — intervention group
Group type: COMPARATOR
Intervention: EES
Number of subjects: 191
Study 25194884 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone/formoterol (100/6 μg) bid
Number of subjects: 22
Study 25194884 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (160/4.5 μg) bid
Number of subjects: 22
Study 23088925 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and communication intervention
Number of subjects: 150
Study 23088925 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counseling intervention
Number of subjects: 150
Study 23088925 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 20492392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound-guided embryo transfer
Number of subjects: 186
Study 20492392 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal ultrasound-guided embryo transfer
Number of subjects: 186
Study 17581531 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained‐release bupropion 150 mg twice daily
Number of subjects: 151
Study 17581531 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 151
Study 17121524 — intervention group
Group type: EXPERIMENTAL
Intervention: l-thyroxine (low-TSH group, 13 patients)
Number of subjects: 25
Study 17121524 — intervention group
Group type: EXPERIMENTAL
Intervention: l-thyroxine plus placebo (euthyroidism group, 12 patients)
Number of subjects: 25
Study 14636939 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 163
Study 14636939 — intervention group
Group type: COMPARATOR
Intervention: Sharp Curettage
Number of subjects: 163
Study 10807468 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g vitamin C (single dose)
Number of subjects: 20
Study 10807468 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g vitamin C daily for 8 weeks
Number of subjects: 20
Study 10807468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10807468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin-mediated dilation
Number of subjects: 20
Study 8632572 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.8 mg goserelin depot, administered every 12 weeks
Number of subjects: 195
Study 8632572 — intervention group
Group type: COMPARATOR
Intervention: 3.6 mg goserelin depot, administered every 4 weeks
Number of subjects: 195
Study 8632572 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.8 mg goserelin depot
Number of subjects: 195
Study 1520646 — intervention group
Group type: EXPERIMENTAL
Intervention: IV streptokinase prehospital (MCCU group, n = 43)
Number of subjects: 145
Study 1520646 — intervention group
Group type: COMPARATOR
Intervention: IV streptokinase in hospital (hospital group, n = 102)
Number of subjects: 145
Study 6402355 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cellulose bound nitroglycerin
Number of subjects: 40
Study 6402355 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cellulose bound nitroglycerin
Number of subjects: 40
Study 6402355 — intervention group
Group type: COMPARATOR
Intervention: 40 mg sustained release isosorbide dinitrate
Number of subjects: 40
Study 6402355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30633722 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept infusions
Number of subjects: 5
Study 28253012 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-enhancement before completing a creativity task
Number of subjects: 5
Study 28253012 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-enhancement before completing a pain-inducing cold-pressor task
Number of subjects: 5
Study 28253012 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-enhancement relevant to the task
Number of subjects: 5
Study 28253012 — intervention group
Group type: COMPARATOR
Intervention: Self-enhancement
Number of subjects: 5
Study 26271839 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Number of subjects: 400
Study 26271839 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.1%
Number of subjects: 400
Study 26271839 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.5%
Number of subjects: 400
Study 24912568 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based appointment systems (WAS)
Number of subjects: 1000
Study 24912568 — intervention group
Group type: COMPARATOR
Intervention: Traditional appointment methods (queuing)
Number of subjects: 1000
Study 24912568 — intervention group
Group type: COMPARATOR
Intervention: Alternative forms of appointment booking systems suggested by doctors
Number of subjects: 1000
Study 24912568 — intervention group
Group type: COMPARATOR
Intervention: On-the-spot appointment option suggested by non-associated professors
Number of subjects: 1000
Study 22044557 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg)
Number of subjects: 81
Study 22044557 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 81
Study 22044557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 19561259 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon method (control group)
Number of subjects: 80
Study 19561259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamp method (clamp group)
Number of subjects: 80
Study 19561259 — intervention group
Group type: EXPERIMENTAL
Intervention: Drip infusion for VCUG
Number of subjects: 80
Study 16771895 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched interventions (information conditions designed to increase positive outcome expectations, decrease negative outcome expectations, or increase self-efficacy)
Number of subjects: 481
Study 16771895 — intervention group
Group type: COMPARATOR
Intervention: Mismatched interventions
Number of subjects: 481
Study 14647133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release oxycodone (CRO)
Number of subjects: 26
Study 14647133 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release morphine (CRM)
Number of subjects: 26
Study 14647133 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine and oxycodone
Number of subjects: 26
Study 10756544 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate gel beads prepared with low molecular size alginate
Number of subjects: 0
Study 10756544 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate gel beads (general)
Number of subjects: 0
Study 10756544 — intervention group
Group type: COMPARATOR
Intervention: Commercial sustained-release tablet (Carvisken)
Number of subjects: 0
Study 8930425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten oral suspension 9 mg/kg once daily (maximum dose, 400 mg/d) for 10 days
Number of subjects: 205
Study 8930425 — intervention group
Group type: COMPARATOR
Intervention: Cefprozil oral suspension 15 mg/kg twice daily (maximum dose, 1000 mg/d) for 10 days
Number of subjects: 205
Study 8930425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 205
Study 8930425 — intervention group
Group type: COMPARATOR
Intervention: Cefprozil
Number of subjects: 205
Study 1473854 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Release (MR) formulation of diltiazem (60 mg)
Number of subjects: 8
Study 1473854 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Release (MR) formulation of diltiazem
Number of subjects: 8
Study 1473854 — intervention group
Group type: COMPARATOR
Intervention: Immediate Release (IR) formulation of diltiazem (60 mg)
Number of subjects: 8
Study 2865156 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blocker (propranolol)
Number of subjects: 3
Study 2865156 — intervention group
Group type: COMPARATOR
Intervention: Combined alpha- and beta-adrenoceptor blocker (labetalol)
Number of subjects: 3
Study 2865156 — intervention group
Group type: COMPARATOR
Intervention: Untreated hypertensives
Number of subjects: 3
Study 31012970 — intervention group
Group type: EXPERIMENTAL
Intervention: Garmin Vivofit 2 activity monitor with behavioral feedback and goal‐setting session and 5 telephone‐delivered health coaching sessions
Number of subjects: 83
Study 31012970 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 29493846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 279
Study 29493846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 279
Study 29493846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 29493846 — intervention group
Group type: EXPERIMENTAL
Intervention: EDITS and IIEF EF domain scores
Number of subjects: 279
Study 29493846 — intervention group
Group type: EXPERIMENTAL
Intervention: EDITS and EHS instrument scores
Number of subjects: 279
Study 27630373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg or 1.0 mg administered at tumor localization and every 2 months for 24 months
Number of subjects: 40
Study 27630373 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 40
Study 24077371 — intervention group
Group type: EXPERIMENTAL
Intervention: GRD (dive on the ground and complete a rolling sequence)
Number of subjects: 10
Study 24077371 — intervention group
Group type: COMPARATOR
Intervention: STD (complete the shuttles while staying on their feet)
Number of subjects: 10
Study 24077371 — intervention group
Group type: EXPERIMENTAL
Intervention: GRD with nose clip
Number of subjects: 10
Study 24077371 — intervention group
Group type: COMPARATOR
Intervention: STD with nose clip
Number of subjects: 10
Study 24077371 — intervention group
Group type: EXPERIMENTAL
Intervention: GRD
Number of subjects: 10
Study 24077371 — intervention group
Group type: COMPARATOR
Intervention: STD
Number of subjects: 10
Study 24077371 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 10
Study 22302233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 20
Study 22302233 — intervention group
Group type: COMPARATOR
Intervention: Social support control group
Number of subjects: 20
Study 19068079 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg delta(9)-THC
Number of subjects: 18
Study 19068079 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg delta(9)-THC
Number of subjects: 18
Study 19068079 — intervention group
Group type: COMPARATOR
Intervention: delta(9)-THC with SR141716A (CB(1) receptor antagonist)
Number of subjects: 18
Study 19068079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17909384 — intervention group
Group type: EXPERIMENTAL
Intervention: PBE‐CPI studies
Number of subjects: 0
Study 16637731 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon 2 bracket
Number of subjects: 60
Study 16637731 — intervention group
Group type: COMPARATOR
Intervention: Conventional twin bracket
Number of subjects: 60
Study 12835430 — intervention group
Group type: EXPERIMENTAL
Intervention: Assure (fluoride‐releasing light‐cured compomer)
Number of subjects: 25
Study 12835430 — intervention group
Group type: COMPARATOR
Intervention: Unite & MIP (chemically‐cured composite resin with moisture‐resistant primer)
Number of subjects: 25
Study 12835430 — intervention group
Group type: EXPERIMENTAL
Intervention: Assure
Number of subjects: 25
Study 11004025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal extubation in the operating room (OR)
Number of subjects: 100
Study 11004025 — intervention group
Group type: COMPARATOR
Intervention: Tracheal extubation in the intensive care unit (ICU)
Number of subjects: 100
Study 8792777 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO experimental group (free fee-for-service chiropractic care)
Number of subjects: 0
Study 8792777 — intervention group
Group type: COMPARATOR
Intervention: HMO control group (95% cost sharing for chiropractic services)
Number of subjects: 0
Study 8792777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee-for-service care (with cost sharing)
Number of subjects: 0
Study 1281732 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser recanalization
Number of subjects: 40
Study 1281732 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic intubation
Number of subjects: 40
Study 6693788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides (gentamicin, tobramycin, amikacin)
Number of subjects: 135
Study 6693788 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-toxic patients)
Number of subjects: 135
Study 29395236 — intervention group
Group type: COMPARATOR
Intervention: 20 mm Hg (low pressure)
Number of subjects: 31
Study 29395236 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mm Hg (high pressure)
Number of subjects: 31
Study 27175657 — intervention group
Group type: EXPERIMENTAL
Intervention: EALM therapy (esomeprazole 40 mg bid and amoxicillin 1 g bid for 5 days, followed by esomeprazole 40 mg bid, levofloxacin 500 mg qd, and metronidazole 500 mg tid, for 5 days)
Number of subjects: 164
Study 27175657 — intervention group
Group type: COMPARATOR
Intervention: 10-day EAL therapy (levofloxacin 500 mg qd, amoxicillin 1 g bid, and esomeprazole 40 mg bid)
Number of subjects: 164
Study 24703972 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen dives
Number of subjects: 10
Study 24703972 — intervention group
Group type: COMPARATOR
Intervention: Air dives
Number of subjects: 10
Study 20840223 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised implementation of the oral health care guideline
Number of subjects: 360
Study 20840223 — intervention group
Group type: COMPARATOR
Intervention: Non-supervised implementation of the oral health care guideline
Number of subjects: 360